Modality
Nanobody
MOA
CGRPant
Target
CGRP
Pathway
Sphingolipid
CRC
Development Pipeline
Preclinical
Mar 2018
→ Feb 2031
PreclinicalCurrent
NCT05369734
1,092 pts·CRC
2022-01→2025-12·Not yet recruiting
NCT08871990
514 pts·CRC
2018-03→2031-02·Terminated
1,606 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-183mo agoInterim· CRC
2031-02-074.9y awayInterim· CRC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Preclinical
Termina…
Preclinical
Not yet…
Catalysts
Interim
2025-12-18 · 3mo ago
CRC
Interim
2031-02-07 · 4.9y away
CRC
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05369734 | Preclinical | CRC | Not yet recr... | 1092 | UPDRS |
| NCT08871990 | Preclinical | CRC | Terminated | 514 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| INC-2432 | Incyte | Phase 2 | CD47 |